Aptevo TherapeuticsAPVO
Market Cap: $1.65M
About: Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Employees: 40
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
4,403% more capital invested
Capital invested by funds: $13.3K [Q1] → $599K (+$586K) [Q2]
800% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 1
80% more funds holding
Funds holding: 10 [Q1] → 18 (+8) [Q2]
47.57% more ownership
Funds ownership: 0.56% [Q1] → 48.13% (+47.57%) [Q2]
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Research analyst outlook
We haven’t received any recent analyst ratings for APVO.